{"transactions":[{"id":730323,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-06-22T20:22:10.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":53600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option to purchase shares of the Issuer's common stock (the \"Stock Option\") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":53600,"derivative":{"exercise_price":1.02,"exercise_date":"2027-06-17","expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":53600},"source":{"system":"sec-edgar","filing":"0001244159-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000124415926000001/primarydocument.xml","form_type":"4"}},{"id":730322,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T20:22:10.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":35700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (the \"RSUs\") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the \"2023 Plan\"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the \"Program\"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":197429,"source":{"system":"sec-edgar","filing":"0001244159-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000124415926000001/primarydocument.xml","form_type":"4"}},{"id":1114751,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2025-06-11T21:14:53.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":53600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option to purchase shares of the Issuer's common stock (the \"Stock Option\") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer."}],"balance_after":53600,"derivative":{"exercise_price":3.92,"exercise_date":"2026-06-10","expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":53600},"source":{"system":"sec-edgar","filing":"0001562180-25-004720","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218025004720/primarydocument.xml","form_type":"4"}},{"id":1114750,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:14:53.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":35700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (the \"RSUs\") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the \"2023 Plan\"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the \"Program\"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer."}],"balance_after":161729,"source":{"system":"sec-edgar","filing":"0001562180-25-004720","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218025004720/primarydocument.xml","form_type":"4"}},{"id":1484677,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-10T20:19:42.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option to purchase shares of the Issuer's common stock (the \"Stock Option\") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":1.07,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001562180-24-004907","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218024004907/primarydocument.xml","form_type":"4"}},{"id":1484676,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T20:19:42.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (the \"RSUs\") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the \"2023 Plan\"), as provided by the Issuer's Third Amended and Restated Non-Employee Director Compensation Program (the \"Program\"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer."}],"balance_after":126029,"source":{"system":"sec-edgar","filing":"0001562180-24-004907","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218024004907/primarydocument.xml","form_type":"4"}},{"id":1862022,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-06-08T20:08:02.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option to purchase shares of the Issuer's common stock (the \"Stock Option\") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":1.2,"exercise_date":"2024-06-06","expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001562180-23-004959","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218023004959/primarydocument.xml","form_type":"4"}},{"id":1862021,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-08T20:08:02.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (the \"RSUs\") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the \"2023 Plan\"), as provided by the Issuer's Second Amended and Restated Non-Employee Director Compensation Program (the \"Program\"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer."}],"balance_after":96029,"source":{"system":"sec-edgar","filing":"0001562180-23-004959","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218023004959/primarydocument.xml","form_type":"4"}},{"id":2151190,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-26T20:07:45.000Z","date":"2022-09-23","kind":"grant","acquired":true,"shares":97063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest pro rata on a monthly basis commencing on October 23,2022 for the next 12 months with full vesting, if not fully vested at such time, on the date of Aravive, Inc.'s next annual meeting of stockholders."}],"balance_after":97063,"derivative":{"exercise_price":0.9152,"exercise_date":"2022-10-23","expiration_date":"2032-09-22","underlying":"Common Stock","underlying_shares":97063},"source":{"system":"sec-edgar","filing":"0001437749-22-023060","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000143774922023060/rdgdoc.xml","form_type":"4"}},{"id":2237499,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-06-09T20:58:33.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option to purchase shares of the Issuer's common stock (the \"Stock Option\") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":20100,"derivative":{"exercise_price":0.45,"exercise_date":"2023-06-08","expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001562180-22-004976","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218022004976/primarydocument.xml","form_type":"4"}},{"id":2237498,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T20:58:33.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (the \"RSUs\") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the \"2014 Plan\"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the \"Program\"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":66029,"source":{"system":"sec-edgar","filing":"0001562180-22-004976","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218022004976/primarydocument.xml","form_type":"4"}},{"id":2571860,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true}}],"security":"Stock Option","published_at":"2021-09-13T20:06:35.000Z","date":"2021-09-10","kind":"grant","acquired":true,"shares":22812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest pro rata on a monthly basis commencing on October 10, 2021 for the next 12 months with full vesting, if not fully vested at such time, on the date of Aravive, Inc.'s next annual meeting of stockholders."}],"balance_after":22812,"derivative":{"exercise_price":3.97,"exercise_date":"2021-10-10","expiration_date":"2031-09-09","underlying":"Common Stock","underlying_shares":22812},"source":{"system":"sec-edgar","filing":"0001437749-21-022011","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000143774921022011/rdgdoc.xml","form_type":"4"}},{"id":2682840,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-06-03T21:27:48.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option to purchase shares of the Issuer's common stock (the \"Stock Option\") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":20100,"derivative":{"exercise_price":3.37,"exercise_date":"2022-06-02","expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001562180-21-004029","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218021004029/primarydocument.xml","form_type":"4"}},{"id":2682839,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T21:27:48.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (the \"RSUs\") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the \"2014 Plan\"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the \"Program\"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":52329,"source":{"system":"sec-edgar","filing":"0001562180-21-004029","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218021004029/primarydocument.xml","form_type":"4"}},{"id":3028005,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-09-17T11:06:25.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":14987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These option vest 1/36th per month."}],"balance_after":14987,"derivative":{"exercise_price":5.99,"exercise_date":"2020-10-15","expiration_date":"2030-09-14","underlying":"Common Stock","underlying_shares":14987},"source":{"system":"sec-edgar","filing":"0000899243-20-025488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924320025488/doc4.xml","form_type":"4"}},{"id":3028004,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-09-17T11:06:25.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":15024,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest pro rata on a monthly basis commencing on October 15, 2020 for the next 12 months with full vesting, if not fully vested at such time, on the date of Aravive, Inc.'s next annual meeting of stockholders."}],"balance_after":15024,"derivative":{"exercise_price":5.99,"exercise_date":"2020-10-15","expiration_date":"2030-09-14","underlying":"Common Stock","underlying_shares":15024},"source":{"system":"sec-edgar","filing":"0000899243-20-025488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924320025488/doc4.xml","form_type":"4"}},{"id":3116053,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-06-09T20:17:27.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the \"Stock Option\"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":20100,"derivative":{"exercise_price":11.96,"exercise_date":"2021-06-05","expiration_date":"2030-06-05","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001562180-20-004357","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218020004357/primarydocument.xml","form_type":"4"}},{"id":3116052,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-09T20:17:27.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the \"RSUs\"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":38629,"source":{"system":"sec-edgar","filing":"0001562180-20-004357","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218020004357/primarydocument.xml","form_type":"4"}},{"id":3476808,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-27T20:53:31.000Z","date":"2019-06-25","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the closing price of the Company's common stock on February 21, 2019, which was the date the option grant was approved by the Compensation Committee of the Board of Directors (the \"Committee\") of EyePoint Pharmaceuticals, Inc. (the \"Registrant\"), subject to stockholder approval of an amendment to the Registrant's 2016 Long Term Incentive Plan (the \"Plan Amendment\")."},{"field":"date","element":"transactionDate","label":"F2","text":"The option grant was approved by the Committee on February 21, 2019, subject to stockholder approval of the Plan Amendment. The Registrant's stockholders approved the Plan Amendment on June 25, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option to purchase, which vested immediately upon Mr. Rogers' departure from the Board, will be exercisable until June 25, 2020"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The option to purchase, which vested immediately upon Mr. Rogers' departure from the Board, will be exercisable until June 25, 2020"}],"balance_after":40000,"derivative":{"exercise_price":2.65,"exercise_date":"2019-06-25","expiration_date":"2020-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001562180-19-003669","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218019003669/primarydocument.xml","form_type":"4"}},{"id":3479899,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2019-06-24T20:31:16.000Z","date":"2019-06-21","kind":"exercise","acquired":false,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a \"change in control\" (as defined in the applicable award agreement) that constitutes a \"change in the ownership or effective control of\" the Company or \"a change in the ownership of a substantial portion of the assets of\" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a \"change in control\" (as defined in the applicable award agreement) that constitutes a \"change in the ownership or effective control of\" the Company or \"a change in the ownership of a substantial portion of the assets of\" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a \"change in control\" (as defined in the applicable award agreement) that constitutes a \"change in the ownership or effective control of\" the Company or \"a change in the ownership of a substantial portion of the assets of\" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0001562180-19-003630","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218019003630/primarydocument.xml","form_type":"4"}},{"id":3479898,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-24T20:31:16.000Z","date":"2019-06-21","kind":"exercise","acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of deferred stock units (\"DSUs\") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the \"Company\")."}],"balance_after":119167,"source":{"system":"sec-edgar","filing":"0001562180-19-003630","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218019003630/primarydocument.xml","form_type":"4"}},{"id":3495509,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-06-10T20:04:44.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the \"Stock Option\").  100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":20100,"derivative":{"exercise_price":4.23,"exercise_date":"2020-06-06","expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001562180-19-003439","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218019003439/primarydocument.xml","form_type":"4"}},{"id":3495508,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-10T20:04:44.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the \"RSUs\").  100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":24929,"source":{"system":"sec-edgar","filing":"0001562180-19-003439","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000156218019003439/primarydocument.xml","form_type":"4"}},{"id":3523705,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-16T21:14:06.000Z","date":"2019-05-14","kind":"grant","acquired":true,"shares":430500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the shares shall vest on June 30, 2020 and the remaining 50% shall vest on June 30, 2021."}],"balance_after":430500,"derivative":{"exercise_price":1.04,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":430500},"source":{"system":"sec-edgar","filing":"0000899243-19-013767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000089924319013767/doc4.xml","form_type":"4"}},{"id":3523704,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-16T21:14:06.000Z","date":"2019-05-14","kind":"grant","acquired":true,"shares":169500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date."}],"balance_after":169500,"derivative":{"exercise_price":1.04,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":169500},"source":{"system":"sec-edgar","filing":"0000899243-19-013767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000089924319013767/doc4.xml","form_type":"4"}},{"id":3645567,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-20T21:51:06.000Z","date":"2019-02-15","kind":"grant","acquired":true,"shares":215328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date."}],"balance_after":215328,"derivative":{"exercise_price":3.27,"expiration_date":"2029-02-15","underlying":"Common Stock","underlying_shares":215328},"source":{"system":"sec-edgar","filing":"0000899243-19-004271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000089924319004271/doc4.xml","form_type":"4"}},{"id":3731952,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-12-13T23:44:13.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":25000,"derivative":{"exercise_price":8.94,"expiration_date":"2028-12-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-030951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318030951/doc4.xml","form_type":"4"}},{"id":3731951,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-12-13T23:44:13.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":11229,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a \"Keryx Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an \"Issuer Option\") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and currently exercisable."}],"balance_after":11229,"derivative":{"exercise_price":10.05,"expiration_date":"2028-06-30","underlying":"Common Stock","underlying_shares":11229},"source":{"system":"sec-edgar","filing":"0000899243-18-030951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318030951/doc4.xml","form_type":"4"}},{"id":3731950,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-12-13T23:44:13.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":11229,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a \"Keryx Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an \"Issuer Option\") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and currently exercisable."}],"balance_after":11229,"derivative":{"exercise_price":17.53,"expiration_date":"2027-06-09","underlying":"Common Stock","underlying_shares":11229},"source":{"system":"sec-edgar","filing":"0000899243-18-030951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318030951/doc4.xml","form_type":"4"}},{"id":3731949,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-12-13T23:44:13.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":11229,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a \"Keryx Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an \"Issuer Option\") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and currently exercisable."}],"balance_after":11229,"derivative":{"exercise_price":15.26,"expiration_date":"2026-05-26","underlying":"Common Stock","underlying_shares":11229},"source":{"system":"sec-edgar","filing":"0000899243-18-030951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318030951/doc4.xml","form_type":"4"}},{"id":3731948,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-12-13T23:44:13.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":18716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a \"Keryx Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an \"Issuer Option\") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and currently exercisable."}],"balance_after":18716,"derivative":{"exercise_price":12.48,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":18716},"source":{"system":"sec-edgar","filing":"0000899243-18-030951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318030951/doc4.xml","form_type":"4"}},{"id":3731947,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T23:44:13.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":11229,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the \"Merger Agreement\"), each share of common stock of Keryx Biopharmaceuticals, Inc. (\"Keryx\")  owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement (the \"Effective Time\") was automatically converted into 0.37433 shares of the Issuer's common stock (the \"Exchange Multiplier\")."}],"balance_after":11229,"source":{"system":"sec-edgar","filing":"0000899243-18-030951","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318030951/doc4.xml","form_type":"4"}},{"id":3733010,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-12-13T16:40:50.000Z","date":"2018-12-12","kind":"disposition_to_issuer","acquired":false,"shares":140000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0000899243-18-030894","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924318030894/doc4.xml","form_type":"4"}},{"id":3733009,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T16:40:50.000Z","date":"2018-12-12","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. (\"Keryx\"), Akebia Therapeutics, Inc. (\"Akebia\") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the \"Merger Agreement\"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the \"Exchange Ratio\"), with fractional shares being paid in cash as provided in the Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. (\"Keryx\"), Akebia Therapeutics, Inc. (\"Akebia\") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the \"Merger Agreement\"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the \"Exchange Ratio\"), with fractional shares being paid in cash as provided in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-030894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924318030894/doc4.xml","form_type":"4"}},{"id":3760734,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-11-16T21:00:32.000Z","date":"2018-11-15","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.13,"exercise_date":"2009-11-18","expiration_date":"2018-11-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029124","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318029124/doc4.xml","form_type":"4"}},{"id":3760733,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T21:00:32.000Z","date":"2018-11-15","kind":"exercise","acquired":true,"shares":100000,"price":1.13,"value":113000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of (i) 100,000 shares of common stock, par value $0.001 per share, of EyePoint Pharmaceuticals, Inc. (the \"Company\") acquired upon exercise of the stock option as described above and (ii) 12,500 shares of common stock of the Company underlying certain deferred stock units (\"DSUs\") previously awarded to the reporting person, with each DSU representing the right to receive one share of common stock of the Company. These DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a \"change in control\" (as defined in the applicable award agreement) that constitutes a \"change in the ownership or effective control of\" the Company or \"a change in the ownership of a substantial portion of the assets of\" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986,"}],"balance_after":112500,"source":{"system":"sec-edgar","filing":"0000899243-18-029124","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318029124/doc4.xml","form_type":"4"}},{"id":3868901,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-07-12T18:01:07.000Z","date":"2018-06-30","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The 30,000 stock options vest as to one-third on each of June 30, 2019, June 30, 2020 and June 30, 2021."}],"balance_after":30000,"derivative":{"exercise_price":3.76,"exercise_date":"2019-06-30","expiration_date":"2028-06-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001114220-18-000078","document":"wf-form4_153143285173847.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000078/wf-form4_153143285173847.xml","form_type":"4"}},{"id":3868900,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-12T18:01:07.000Z","date":"2018-06-30","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 30, 2019, June 30, 2020 and June 30, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 19,999 shares of restricted stock."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001114220-18-000078","document":"wf-form4_153143285173847.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000078/wf-form4_153143285173847.xml","form_type":"4"}},{"id":3880357,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2018-06-29T20:00:40.000Z","date":"2018-06-27","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a \"change in control\" (as defined in the applicable award agreement) that constitutes a \"change in the ownership or effective control of\" the Company or \"a change in the ownership of a substantial portion of the assets of\" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a \"change in control\" (as defined in the applicable award agreement) that constitutes a \"change in the ownership or effective control of\" the Company or \"a change in the ownership of a substantial portion of the assets of\" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a \"change in control\" (as defined in the applicable award agreement) that constitutes a \"change in the ownership or effective control of\" the Company or \"a change in the ownership of a substantial portion of the assets of\" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-18-018709","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318018709/doc4.xml","form_type":"4"}},{"id":3880356,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-29T20:00:40.000Z","date":"2018-06-27","kind":"exercise","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of deferred stock units (\"DSUs\") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the \"Company\")."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0000899243-18-018709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318018709/doc4.xml","form_type":"4"}},{"id":3882933,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2018-06-26T18:12:02.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the \"Company\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a \"change in control\" (as defined in the applicable award agreement) that constitutes a \"change in the ownership or effective control of\" the Company or \"a change in the ownership of a substantial portion of the assets of\" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder."}],"balance_after":6667,"derivative":{"exercise_date":"2019-06-21","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000899243-18-018096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318018096/doc4.xml","form_type":"4"}},{"id":3882932,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-06-26T18:12:02.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":26667,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":26667,"derivative":{"exercise_price":1.95,"exercise_date":"2019-06-21","expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":26667},"source":{"system":"sec-edgar","filing":"0000899243-18-018096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924318018096/doc4.xml","form_type":"4"}},{"id":3957147,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-04-26T00:24:22.000Z","date":"2018-04-23","kind":"grant","acquired":true,"shares":144000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options exercisable as to 1/4th on the first anniversary of the vesting start date and an additional 1/48th monthly thereafter until the fourth anniversary of the vesting start date."}],"balance_after":144000,"derivative":{"exercise_price":3.59,"expiration_date":"2028-04-23","underlying":"Common Stock","underlying_shares":144000},"source":{"system":"sec-edgar","filing":"0000899243-18-010747","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000089924318010747/doc4.xml","form_type":"4"}},{"id":4126102,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2017-12-19T21:08:46.000Z","date":"2017-12-15","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the right to receive one share of the common stock of pSivida Corp. (the \"Company\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a \"change in control\" (as defined in the applicable award agreement) that constitutes a \"change in the ownership or effective control of\" the Company or \"a change in the ownership of a substantial portion of the assets of\" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder."}],"balance_after":12500,"derivative":{"exercise_date":"2018-06-27","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-17-029160","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924317029160/doc4.xml","form_type":"4"}},{"id":4126101,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-12-19T21:08:46.000Z","date":"2017-12-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":1.77,"exercise_date":"2018-06-27","expiration_date":"2027-06-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-17-029160","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924317029160/doc4.xml","form_type":"4"}},{"id":4128522,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-18T22:06:43.000Z","date":"2017-12-14","kind":"grant","acquired":true,"shares":293006,"price":5.5,"value":1611533.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options exercisable as to 1/4th on the first anniversary of the vesting start date and an additional 1/48th monthly thereafter until the fourth anniversary of the vesting start date"}],"balance_after":0,"derivative":{"exercise_price":5.5,"expiration_date":"2027-11-15","underlying":"Common Stock","underlying_shares":293006},"source":{"system":"sec-edgar","filing":"0000899243-17-029052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000089924317029052/doc4.xml","form_type":"4"}},{"id":4276395,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2017-06-20T16:06:01.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The 30,000 stock options vest as to one-third on each of June 9, 2018, June 9, 2019 and June 9, 2020."}],"balance_after":30000,"derivative":{"exercise_price":6.56,"exercise_date":"2018-06-09","expiration_date":"2027-06-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-17-016756","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924317016756/doc4.xml","form_type":"4"}},{"id":4276394,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-20T16:06:01.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 9, 2018, June 9, 2019 and June 9, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 16,666 shares of restricted stock."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0000899243-17-016756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924317016756/doc4.xml","form_type":"4"}},{"id":4521947,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":36293,"kind":"person","name":"ROGERS MICHAEL W","position":1,"cik":"0001244159","reported_name":"ROGERS MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-12-14T18:02:35.000Z","date":"2016-12-12","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":3.49,"exercise_date":"2017-07-21","expiration_date":"2026-07-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-16-035517","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1244159/000089924316035517/doc4.xml","form_type":"4"}}]}